Sign in

    Farhana Sakloth

    Research Analyst at Ladenburg Thalmann

    Farhana Sakloth is an Equity Research Analyst at Ladenburg Thalmann, specializing in coverage of the biotechnology and life sciences sectors with a focus on clinical-stage pharmaceutical companies. She has participated in earnings calls and conducted research on companies such as SCYNEXIS and Palatin Technologies, demonstrating engagement with firms advancing novel therapeutics. Prior to joining Ladenburg Thalmann, Sakloth earned a Doctorate Degree from Virginia Commonwealth University and has built expertise in finance and consumer services since entering the industry. She maintains active professional credentials through FINRA and contributes in-depth analysis to Ladenburg’s institutional and corporate clients.

    Farhana Sakloth's questions to SCYNEXIS (SCYX) leadership

    Farhana Sakloth's questions to SCYNEXIS (SCYX) leadership • Q2 2022

    Question

    On behalf of Michael Higgins, Farhana Sakloth asked for more details on the timing of FDA discussions for the IV formulation's Phase 1 data, the data readout timeline for the FURI and CARES studies, and the expected data readout for the VANQUISH study.

    Answer

    Chief Medical Officer Dr. David Angulo stated that the company is compiling the positive Phase 1 data for the IV formulation and aims to discuss a potential abbreviated development path with the FDA by the end of 2022. He clarified that data from the FURI and CARES studies are expected in 2024, intended to be part of a combined regulatory submission with the MARIO study. He also projected that data from the VANQUISH study would be available in the second half of 2024.

    Ask Fintool Equity Research AI